Irbesartán/Hidroclorotiazida Alter (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Essential hypertension: lowers systolic and diastolic blood pressure to target levels.
• Secondary hypertension: assists in controlling blood pressure when it results from another underlying condition.
• High cardiovascular‑risk patients: contributes to overall risk reduction by maintaining optimal blood pressure.

• Irbesartan selectively blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of water and electrolytes. The combined actions reduce peripheral vascular resistance and plasma volume, leading to a sustained decrease in arterial blood pressure.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Fatigue or weakness.
• Increased urination.
• Electrolyte disturbances, especially low potassium.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance.
• Acute kidney injury or worsening renal function.
• Hyperkalemia when combined with potassium‑sparing agents.
• Allergic reactions such as rash, angioedema, or anaphylaxis.
• Blood dyscrasias including leukopenia or thrombocytopenia.
• Hepatic dysfunction or jaundice.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Electrolyte and renal function checks: regularly evaluate potassium, sodium, and creatinine.
• Contraindication in severe renal impairment: avoid or adjust dose.
• Caution in diabetes mellitus: monitor blood glucose as diuretic may affect control.
• Pregnancy and lactation: safety category unknown; use only if benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines; careful review is essential.

Major Interactions (Avoid)

• Aliskiren: combined use can increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: additive effects on blood pressure and renal function.
• Lithium: increased lithium levels and toxicity.
• NSAIDs (high dose): can reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to avoid hypotension.
• CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations.
• Antidiabetic agents: diuretic effect may affect glucose control.
• Anticoagulants: thiazide component may enhance anticoagulant effect.
• Digoxin: electrolyte changes can predispose to digoxin toxicity.